Rash to the mTOR inhibitor everolimus systematic review and meta-analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 3, 2014, Pages 266-271

  Ramirez Fort, Marigdalia K ^a   Case, Emily C ^b   Rosen, Alyx C ^b   Cerci, Felipe B ^d   Wu, Shenhong ^c   Lacouture, Mario E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Everolimus; Mtor inhibitor; Skin rash

Indexed keywords

EVEROLIMUS; EXEMESTANE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

CANCER INCIDENCE; CANCER PATIENT; DRUG ERUPTION; HUMAN; MEDLINE; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WEB OF SCIENCE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; EPIDEMIOLOGY; INCIDENCE; QUALITY OF LIFE; RISK;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ERUPTIONS; HUMANS; INCIDENCE; QUALITY OF LIFE; RISK; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84905037265     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318277d62f     Document Type: Review

References (37)

1. Proud CG. The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst). 2004;3:927-934.
2. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004-7014.
3. Dhillon T, Mauri FA, Bellezza G, et al. Overexpression of the mammalian target of rapamycin: A novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010;5:314-319.
4. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
5. Sanchez-Fructuoso AI. Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008;4:807-819.
6. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11:5319-5328.
7. Albert S, Serova M, Dreyer C, et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010;19:919-930.
8. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-1811.
9. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
10. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
11. Fuchs U, Zittermann A, Hakim-Meibodi K, et al. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: A two-year follow-up study. Transplant Proc. 2011;43:1839-1846.
12. Spagnoletti G, Favi E, Gargiulo A, et al. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study. Transplant Proc. 2011;43:1010-1012.
13. Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47:1287-1298.
14. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438-2446.
15. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630-2637.
16. Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28:1904-1910.
17. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27:4536-4541.
18. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320-324.
19. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116: 5415-5419.
20. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010;16:5900-5907.
21. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol. 2010;28:69-76.
22. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-529.
23. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010;16:5900-5907.
24. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol. 2009;20:1674-1681.
25. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6: 125-129.
26. Balagula Y, Rosen A, Tan BH, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078-5083.
27. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4:107-119.
28. Gandhi M, Kuzel T, Lacouture M. Eosinophilic rash secondary to temsirolimus. Clin Genitourin Cancer. 2009;7:E34-E36.
29. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-326.
30. Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16:16-26.
31. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803-812.
32. Nomura M, He Z, Koyama I, et al. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog. 2003;38:25-32.
33. Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature. 2006;441:362-365.
34. Affara NI, Trempus CS, Schanbacher BL, et al. Activation of Akt and mTOR in CD34 +/K15 + keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res. 2006;26:2805-2820.
35. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-3171.
36. Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116:210-215.
37. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10:345-356.